The DPP6 (dipeptidyl peptidase-like protein 6) antibody targets a protein belonging to the dipeptidyl peptidase IV family, though it lacks enzymatic activity. DPP6. also known as DPPX, is a type II transmembrane glycoprotein that modulates voltage-gated potassium channels (Kv4 family), influencing neuronal and cardiac excitability. It is highly expressed in the brain, pancreas, and heart. Research on DPP6 antibodies primarily focuses on understanding its role in regulating ion channel function, synaptic plasticity, and neural network dynamics.
DPP6 has been implicated in neurodevelopmental and neurodegenerative disorders. Studies link DPP6 gene variations to susceptibility to Alzheimer’s disease, Parkinson’s disease, and amyotrophic lateral sclerosis (ALS). Additionally, altered DPP6 expression is observed in certain cancers, suggesting potential as a biomarker. Autoantibodies against DPP6 are rare but associated with autoimmune encephalitis, highlighting its relevance in neuroimmunology.
Antibodies targeting DPP6 are critical tools for immunohistochemistry, Western blotting, and functional studies to map protein distribution, quantify expression levels, and dissect molecular interactions. Their development aids in exploring DPP6’s contribution to disease mechanisms and therapeutic targeting. Ongoing research aims to clarify its dual roles in physiology and pathology, bridging gaps between ion channel biology and complex neurological conditions.